Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15003
UPID:
CND2_HUMAN
Alternative names:
Barren homolog protein 1; Chromosome-associated protein H; Non-SMC condensin I complex subunit H; XCAP-H homolog
Alternative UPACC:
Q15003; B4E189; Q8TB87
Background:
Condensin complex subunit 2, known by alternative names such as Barren homolog protein 1 and Non-SMC condensin I complex subunit H, plays a pivotal role in chromatin structure modification. It is essential for converting interphase chromatin into mitotic-like condensed chromosomes, facilitating accurate DNA replication and cell division. This protein's involvement in early neurogenesis, particularly in ensuring proper mitotic chromosome condensation in neuron stem cells, is crucial for brain development and cortex size.
Therapeutic significance:
Linked to Microcephaly 23, primary, autosomal recessive, a condition characterized by significantly reduced head circumference and brain weight, Condensin complex subunit 2's mutation underscores its critical role in neurodevelopment. Understanding the role of Condensin complex subunit 2 could open doors to potential therapeutic strategies for treating microcephaly and related neurodevelopmental disorders.